Literature DB >> 16739393

Adiponectin produced in coronary circulation regulates coronary flow reserve in nondiabetic patients with angiographically normal coronary arteries.

Haruhiko Date1, Takuroh Imamura, Takeshi Ideguchi, Junji Kawagoe, Takahiro Sumi, Hiroyuki Masuyama, Hisamitsu Onitsuka, Tetsunori Ishikawa, Toshiro Nagoshi, Tanenao Eto.   

Abstract

BACKGROUND: Epicardial adipose tissue expresses adiponectin protein, and its expression is significantly lower in patients with severe coronary artery disease (CAD) than in those without CAD. Transcoronary adiponectin levels are significantly decreased in nondiabetic but not in diabetic patients with CAD. Adiponectin is also an important adipocytokine that is linked to insulin resistance and reduces coronary microvascular function. HYPOTHESIS: Adiponectin may play a significant role in the localized coronary circulation. The present study examines the local dynamics of adiponectin in the coronary circulation in nondiabetic individuals with normal coronary arteries and the relationship between adiponectin and coronary microvasculature function.
METHODS: We examined 22 consecutive nondiabetic patients whose coronary arteries were angiographically normal. Plasma levels of adiponectin were measured in blood samples that were simultaneously collected from the orifice of the left coronary artery (LCA) and the great cardiac vein (GCV). To evaluate the function of the coronary microcirculation, we measured coronary flow velocity at maximal hyperemia using a Doppler wire. Coronary flow reserve (CFR) was obtained from the ratio of hyperemia to the baseline coronary flow velocity.
RESULTS: Plasma adiponectin levels in the GCV (median 6.95 microg/ml) were significantly higher than those in the LCA (median 6.60 microg/ml, p < 0.0005). The difference in plasma adiponectin levels between GCV and LCA significantly correlated with CFR (R = 0.451, p < 0.05).
CONCLUSIONS: Adiponectin is locally produced in the coronary circulation. This protein may participate in modulating the coronary circulation of nondiabetic patients with angiographically normal coronary arteries.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16739393      PMCID: PMC6654653          DOI: 10.1002/clc.4960290508

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  7 in total

Review 1.  Protective vascular and myocardial effects of adiponectin.

Authors:  Barry J Goldstein; Rosario G Scalia; Xin L Ma
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2008-11-25

Review 2.  Brown adipose tissue: The heat is on the heart.

Authors:  Robrecht Thoonen; Allyson G Hindle; Marielle Scherrer-Crosbie
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-04-15       Impact factor: 4.733

Review 3.  The role of perivascular adipose tissue in vascular smooth muscle cell growth.

Authors:  Chao-Yu Miao; Zhi-Yong Li
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

Review 4.  Perivascular adipose tissue and its role in type 2 diabetes and cardiovascular disease.

Authors:  Rick I Meijer; Erik H Serne; Yvo M Smulders; Victor W M van Hinsbergh; John S Yudkin; Etto C Eringa
Journal:  Curr Diab Rep       Date:  2011-06       Impact factor: 4.810

5.  Perivascular Fat and the Microcirculation: Relevance to Insulin Resistance, Diabetes, and Cardiovascular Disease.

Authors:  A J Houben; E C Eringa; A M Jonk; E H Serne; Y M Smulders; C D Stehouwer
Journal:  Curr Cardiovasc Risk Rep       Date:  2011-11-22

6.  Pericardial fat and myocardial perfusion in asymptomatic adults from the Multi-Ethnic Study of Atherosclerosis.

Authors:  Tina E Brinkley; Michael Jerosch-Herold; Aaron R Folsom; J Jeffrey Carr; W Gregory Hundley; Matthew A Allison; David A Bluemke; Gregory L Burke; Moyses Szklo; Jingzhong Ding
Journal:  PLoS One       Date:  2011-12-09       Impact factor: 3.240

Review 7.  Exercise effects on perivascular adipose tissue: endocrine and paracrine determinants of vascular function.

Authors:  B C S Boa; J S Yudkin; V W M van Hinsbergh; E Bouskela; E C Eringa
Journal:  Br J Pharmacol       Date:  2017-03-16       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.